Stephen Willey
Stock Analyst at Stifel
(3.12)
# 1,109
Out of 4,884 analysts
132
Total ratings
40.43%
Success rate
2.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Reinstates: Buy | $30 | $13.79 | +117.55% | 1 | Jul 1, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $28 | $15.89 | +76.21% | 1 | Jun 25, 2025 | |
| INCY Incyte | Upgrades: Buy | $75 → $107 | $68.45 | +56.32% | 6 | Jun 16, 2025 | |
| MGNX MacroGenics | Maintains: Hold | $6 → $5 | $1.46 | +242.47% | 3 | May 14, 2025 | |
| EXEL Exelixis | Maintains: Hold | $36 → $38 | $46.15 | -17.66% | 18 | May 14, 2025 | |
| BOLT Bolt Biotherapeutics | Maintains: Hold | $25 → $20 | $5.92 | +237.84% | 4 | May 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $36 → $35 | $12.73 | +174.94% | 5 | Apr 9, 2025 | |
| NKTX Nkarta | Maintains: Buy | $15 → $14 | $1.75 | +700.00% | 3 | Mar 27, 2025 | |
| VOR Vor Biopharma | Maintains: Buy | $12 → $5 | $1.91 | +161.78% | 5 | Mar 21, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $12 → $10 | $3.80 | +163.16% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.43 | +179.72% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $97 → $96 | $97.80 | -1.84% | 6 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $27 → $2.5 | $1.36 | +83.82% | 7 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $120 | $1.89 | +6,249.21% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $28 | $13.04 | +114.72% | 6 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $9.03 | +420.49% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $0.70 | +475.37% | 7 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $34 → $3 | $2.06 | +45.63% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $7 | $2.68 | +161.19% | 10 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $1.76 | +127.27% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $33.26 | +86.41% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $2.78 | +223.74% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.93 | +521.76% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $1.33 | +21,554.14% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $2.91 | +621.65% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $0.90 | +343.95% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $331.91 | -62.94% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $43.00 | +9.30% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $57.50 | +89.57% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $19.21 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $7.79 | +195.25% | 5 | Feb 7, 2018 |
Celcuity
Jul 1, 2025
Reinstates: Buy
Price Target: $30
Current: $13.79
Upside: +117.55%
Crescent Biopharma
Jun 25, 2025
Initiates: Buy
Price Target: $28
Current: $15.89
Upside: +76.21%
Incyte
Jun 16, 2025
Upgrades: Buy
Price Target: $75 → $107
Current: $68.45
Upside: +56.32%
MacroGenics
May 14, 2025
Maintains: Hold
Price Target: $6 → $5
Current: $1.46
Upside: +242.47%
Exelixis
May 14, 2025
Maintains: Hold
Price Target: $36 → $38
Current: $46.15
Upside: -17.66%
Bolt Biotherapeutics
May 13, 2025
Maintains: Hold
Price Target: $25 → $20
Current: $5.92
Upside: +237.84%
Nurix Therapeutics
Apr 9, 2025
Maintains: Buy
Price Target: $36 → $35
Current: $12.73
Upside: +174.94%
Nkarta
Mar 27, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $1.75
Upside: +700.00%
Vor Biopharma
Mar 21, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $1.91
Upside: +161.78%
AbCellera Biologics
Feb 28, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $3.80
Upside: +163.16%
Feb 27, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.43
Upside: +179.72%
Feb 21, 2025
Maintains: Buy
Price Target: $97 → $96
Current: $97.80
Upside: -1.84%
Jan 10, 2025
Downgrades: Hold
Price Target: $27 → $2.5
Current: $1.36
Upside: +83.82%
Nov 14, 2024
Maintains: Buy
Price Target: $150 → $120
Current: $1.89
Upside: +6,249.21%
Oct 28, 2024
Maintains: Buy
Price Target: $21 → $28
Current: $13.04
Upside: +114.72%
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $9.03
Upside: +420.49%
Aug 20, 2024
Maintains: Buy
Price Target: $8 → $4
Current: $0.70
Upside: +475.37%
Jul 9, 2024
Downgrades: Hold
Price Target: $34 → $3
Current: $2.06
Upside: +45.63%
Apr 12, 2024
Maintains: Hold
Price Target: $7
Current: $2.68
Upside: +161.19%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $1.76
Upside: +127.27%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $33.26
Upside: +86.41%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $2.78
Upside: +223.74%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $1.93
Upside: +521.76%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $1.33
Upside: +21,554.14%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $2.91
Upside: +621.65%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $0.90
Upside: +343.95%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $331.91
Upside: -62.94%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $43.00
Upside: +9.30%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $57.50
Upside: +89.57%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $19.21
Upside: -
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $7.79
Upside: +195.25%